Results 11 to 20 of about 2,979 (199)
Drug Design, Development and Therapy, 2016 Tadakatsu Nakamura,1 Tomoko Kubota,1 Atsushi Iwakaji,1 Masayoshi Imada,1 Margit Kapás,2 Yasunori Morio1 1Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan; 2Developmental Drug Metabolism and ...
Tadakatsu Nakamura
exaly +3 more sources
Cariprazine for Acute and Maintenance Treatment of Adults With Schizophrenia: An Evidence-Based Review and Place in Therapy [PDF]
Neuropsychiatric Disease and Treatment, 2018 Leslie Citrome Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Abstract: Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia.
Leslie Citrome
exaly +4 more sources
Case Report: Long-Acting Oral Cariprazine [PDF]
Frontiers in Psychiatry, 2022 IntroductionCariprazine is a third-generation antipsychotic, approved for the treatment of schizophrenia and bipolar disorder and used off-label for schizoaffective disorder and treatment-resistant depression. Cariprazine is a partial agonist at dopamine
Emanuela Dyrmishi +7 more
doaj +2 more sources
Cariprazine Use in Early Psychosis: Three Case Reports
Frontiers in Psychiatry, 2021 Objective: Cariprazine is a new atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia (1, 2) and for the treatment of manic or mixed episodes associated with bipolar I disorder (1).
Ricardo Coentre +5 more
doaj +2 more sources
Therapeutic Advances in Psychopharmacology, 2020 Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as ‘atypical’ second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania ...
Debbi Ann Morrissette, Stephen Stahl
exaly +2 more sources
Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis [PDF]
The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.Abstract The US FDA recently accepted efficacy extrapolation from adult to pediatric patients for atypical antipsychotics in the treatment of schizophrenia (SCZ) and bipolar mania (BPM), considering the similarity in both disease and exposure‐response relationships for this class of drugs.
Shams Ismaeil +5 more
wiley +2 more sources
CPT: Pharmacometrics & Systems PharmacologyCariprazine is a potent D3‐preferring dopamine D3/D2 receptor partial agonist, a serotonin 5‐HT1A receptor partial agonist, and a serotonin 5‐HT2B receptor antagonist approved for the treatment of a variety of psychiatric disorders.
Md Mahbubul Huq Riad +3 more
doaj +2 more sources
Drug Design, Development and Therapy, 2019 Béla Kiss, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky, Bence Farkas, Norbert Kirschner, Etelka Bolf-Terjéki, Ottilia Balázs, Bal ...
Zsolt Nemethy +2 more
exaly +2 more sources
Therapeutics and Clinical Risk Management, 2013 Silvio Caccia, Roberto William Invernizzi, Alessandro Nobili, Luca Pasina IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Abstract: Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration ...
Caccia S +3 more
doaj +1 more source
Cariprazine Augmentation in Inadequate Clozapine Response: A Case Series [PDF]
Journal of Clinical and Diagnostic ResearchManaging patients with treatment-resistant schizophrenia who do not respond adequately to Clozapine poses a challenge. Cariprazine, with its unique mechanism of action, may be an option for such patients.
SS Asha Charitha +4 more
doaj +2 more sources